Correlation Engine 2.0
Clear Search sequence regions


  • antidiabetics (4)
  • blood (1)
  • cachexia (10)
  • cancer (7)
  • cardiac index (1)
  • cardiac muscles (1)
  • collagen (1)
  • dapagliflozin (1)
  • DPP4 (1)
  • heart (3)
  • heart rate (1)
  • helps (1)
  • humans (1)
  • insulin (1)
  • metformin (3)
  • potassium (1)
  • serum (1)
  • SGLT2 (1)
  • sodium (3)
  • study outcomes (1)
  • vildagliptin (1)
  • weights (1)
  • Sizes of these terms reflect their relevance to your search.

    So far, the cardio-protective potential of antidiabetics is proved, but their effect on cardiovascular complications associated with cancer cachexia is not explored until now. Insulin resistance and glucose intolerance along with systemic inflammation are prominent in cachexia but the potential effect of antidiabetic agents especially those belonging to biguanide, DPP4 inhibitors and SGLT2 on the heart are not studied till now. In present study, the effect of metformin, vildagliptin, teneligliptin, dapagliflozin and empagliflozin on cardiovascular complications associated with cancer cachexia by using B16F1 induced metastatic cancer cachexia and urethane-induced cancer cachexia was studied. These antidiabetic agents proved to be beneficial against cachexia-induced atrophy of the heart, preserved ventricular weights, maintained cardiac hypertrophic index, preserved the wasting of cardiac muscles assessed by HE staining, Masson trichrome staining, periodic acid Schiff staining and picro-Sirius red staining. Altered cardiac gene expression was attenuated after treatment with selected antidiabetics, thus preventing cardiac atrophy. Also, antidiabetic agents treatment improved the serum creatinine kinase MB, Sodium potassium ATPase and collagen in the heart. Reduction in blood pressure and heart rate was observed after treatment with antidiabetic agents. Results of our study show that the selected antidiabetics prove to be beneficial in attenuating the cardiac atrophy and helps in regulation of hemodynamic stauts in cancer cachexia-induced cardiovascular complications. Our study provides some direction towards use of selected antidiabetic agents in the management of cardiovascular complications associated with cancer cachexia and the study outcomes can be useful in desiging clinical trials. © 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

    Citation

    Vivek R Bora, Dhruv Gohel, Rajesh Singh, Bhoomika M Patel. Evaluation of selected antidiabetics in cardiovascular complications associated with cancer cachexia. Molecular and cellular biochemistry. 2023 Apr;478(4):807-820

    Expand section icon Mesh Tags

    Expand section icon Substances


    PMID: 36098898

    View Full Text